Baekeland Fonds Home Baekeland Fonds I Baekeland Fonds II English Nederlands
ActoGenix acquired by Intrexon PDF

Ghent University spin-off ActoGenix has been acquired by Intrexon, a leader in synthetic biology.

ActoGenix is a clinical stage biopharmaceutical company forging a new frontier in cellular therapeutics. Their TopAct platform enables the molecular engineering of food-grade microbes to generate biologically-contained ActoBiotics for in situ expression and secretion of novel biotherapeutic proteins and peptides including cytokines, enzymes, hormones, and monoclonal antibodies to the oral and gastrointestinal tract. This groundbreaking class of orally available biopharmaceuticals has the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and autoimmune diseases.

Intrexon’s exclusive channel collaborators currently utilize the company’s suite of technologies in cellular and gene therapies for cancer, orphan genetic disorders, blindness, infectious diseases, tissue repair, as well as synthetic biology-mediated production of APIs. The addition of the ActoGeniX platform brings two more clinical stage assets to the Intrexon portfolio, and complements the broadest collection of tools available for current and future partners to enable innovative solutions for the next generation of biotechnology. ActoBiotics offer the unique ability to deliver a vast number of biological and small molecule effectors selectively to the oral and gastrointestinal tract opening a pipeline of opportunities that cannot be achieved through customary delivery mechanisms like injectable medicines. By focusing on biopharmaceuticals with known pharmacological activity, documented efficacy and established safety profiles, the development risk for existing and potential partners is substantially lower than for newly discovered drug compounds.